Compare ImmunityBio Inc. Common Stock (IBRX) vs L3Harris Technologies Inc (LHX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ImmunityBio Inc. Common Stock vs L3Harris Technologies Inc — how do they compare? ImmunityBio Inc. Common Stock trades at $10.03 (market cap $10.51B), while L3Harris Technologies Inc trades at $236.77 (market cap $44.12B). The key difference: L3Harris Technologies Inc is far larger — about 4.2× ImmunityBio Inc. Common Stock's market cap, and L3Harris Technologies Inc pays a 2.11% dividend while ImmunityBio Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold ImmunityBio Inc. Common Stock for 0 Days and L3Harris Technologies Inc for 55 Days on average.
| IBRX | LHX | |
|---|---|---|
Market Cap | $10.51B | $44.12B |
Volume | 10,445,785 | 1,202,852 |
Sector | Health | Industrials |
52-Week High | $11.55 | $378.48 |
52-Week Low | $1.98 | $233.63 |
Typical Hold Time | 0 Days | 55 Days |
Enterprise Value | $10.97B | $54.56B |
Dividend Yield | — | 2.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
LHX trades at $233.63, down 1.79% today, with a bearish technical signal despite strong fundamentals. The company reported three consecutive quarterly EPS beats, with Q3 2026 results pending. Recent contract wins include a $6 billion THAAD propulsion deal with Lockheed Martin. Valuation metrics show a P/E of 23.6 and P/S of 1.92, with improving profit margins reaching 7.34% in 2025.
Analyst consensus remains strongly bullish with a $340 price target (45% upside), though legal investigations pose near-term risk. The stock offers solid revenue growth and dividend income, but investors should monitor the multiple law firm investigations and technical weakness. Long-term prospects appear favorable given defense budget tailwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ImmunityBio Inc. Common Stock
ImmunityBio develops immune-based therapies for cancer and infectious diseases. Its programs are designed to activate and strengthen the body’s immune response.
Read more on IBRX →About L3Harris Technologies Inc
L3Harris Technologies was created in 2019 from the merger of L3 Technologies and Harris, two defense contractors that provide products for the command, control, communications, computers, intelligence, surveillance, and reconnaissance (C4ISR) market. The firm also has smaller operations serving the civil government, particularly the Federal Aviation Administration's communication infrastructure, and produces various avionics for defense and commercial aviation.
Read more on LHX →
